ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
ESSA Pharma Inc. (EPIX)
Last essa pharma inc. earnings: 2/13 05:48 pm
Check Earnings Report
US:NASDAQ Investor Relations:
essapharma.com/investors
Company Research
Source: PR Newswire
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPCPhase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QDAcross all dosing cohorts, 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Jan. 25, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium, taking place January 25 - 27, 2024, in San Francisco, CA. Masofaniten is a first-in-class N-terminal domain androgen
Show less
Read more
Impact Snapshot
Event Time:
EPIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPIX alerts
High impacting ESSA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
EPIX
News
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferencePR Newswire
- ESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its Business [Yahoo! Finance]Yahoo! Finance
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSPR Newswire
- Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?PR Newswire
- ESSA Pharma Inc (EPIX) Reports Q1 Fiscal 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
EPIX
Earnings
- 2/13/24 - Beat
EPIX
Sec Filings
- 4/25/24 - Form 4
- 4/5/24 - Form 4
- 4/5/24 - Form S-8
- EPIX's page on the SEC website